SER Serina Therapeutics, Inc. Insider Trading

Director Karen J Wilson purchases 20,000 shares (20.0K shares) for $37,000.00 across two transactions at Serina Therapeutics (SER), establishing first holding.

Karen J Wilson, a Director at Serina Therapeutics, made 2 purchases totaling 20,000 shares for $37,000.00, establishing an initial stake in the company. The purchases occurred at $1.77 on 2026-05-21 and $1.93 on 2026-05-22, with a blended average price of $1.85. This transaction warrants attention given the company's financial profile: net income of $-6.9M in the most recent period and full-year unprofitability, though revenue growth of 132.1% year-over-year indicates accelerating top-line performance. A director purchasing shares for the first time creates a change in insider positioning at a company in growth phase but not yet profitable, meriting investor review of the acquisition's strategic rationale.

Director Richard Peter Marshall bought 12,183 shares at $1.65 in first transaction; stock down 75.0% from 52-week high of $7.92

Director Richard Peter Marshall acquired 12,183 shares at $1.65 on 2026-05-19, representing his first open-market purchase at Serina Therapeutics. The transaction occurs after the stock has declined 75.0% from its 52-week high of $7.92, placing it near the low end of the 52-week range of $1.22–$7.92. The company remains unprofitable with net income of $-6,898,000.00 and zero revenue in the latest quarter, though it reported annual revenue growth of +132.1% year-over-year. The purchase warrants examination of whether it reflects conviction in a turnaround narrative or is simply opportunistic positioning at depressed levels in a cash-burning enterprise.